Microba Life Sciences Limited · ASX:MAP
Microba Life Sciences — NWR Virtual Healthcare Investor Conference 2023
25 slides from Microba Life Sciences's conference presentation, Mar 21, 2023
Slide 1: ASX Announcement: NWR Virtual Healthcare Investor Conference Presentation
ASX Announcement 21 March 2023 NWR Virtual Healthcare Investor Conference Presentation Microba Life Sciences Limited (ASX: MAP) (“Microba”), is pleased to announce that it will present at the NWR Virtual Healthcare Investor Conference today, Tuesday 21 March 2023, at 10:20am AEDT (Sydney/Melbourne)
Slide 2: Transforming health through the human microbiome
For personal use only Transforming health through the human microbiome 21 March 2023 | Authorised for release by the CEO & Chairman
Slide 3: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). For personal use only Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation.
Slide 4: Two core business segments driven by a proprietary databank
Two core business segments driven by a proprietary databank For personal use only Services Databank Therapeutics Proprietary databank Data Insights Health Data Customer Novel Testing Biome Data Therapies Microba provides testing Data-driven therapeutics and data analysis for a fee Driving discovery
Slide 5: Company Snapshot
Company Snapshot For personal use only Continuous YoY Partnerships with market leaders Large, unique, proprietary revenue growth over incl. SYNLAB (GR:SYAB), microbiome databank 5 years of operations Sonic Healthcare (ASX: SHL), Genova Diagnostics, and G42 3 key therapeutic programs World-leading te
Slide 6: Recent Milestones
Recent Milestones For personal use only STRATEGIC INVESTMENT & EXPANSION INTO ITALY, NEXT GENERATION PARTNERSHIP PORTUGAL, CZECH REPUBLIC & HEALTHCARE TESTING TÜRKIYE LAUNCHED Sonic acquired a 19.99% stake in Microba and entered into a Signed, commenced and first New MetaXplore™ test distribution pa
Slide 7: Microbiome Services
For personal use only Microbiome Services Driving global revenues and data growth 6
Slide 8: World-leading microbiome analysis technology
Other Microba Technology Technology For personal use only World-leading microbiome analysis technology unlocks routine testing and microbiome therapies up to 95% coverage1 up to 34x more accurate2 Published in 1 Calculated by analysing more than 10k samples across Microba’s databank Illustrative vis
Slide 9: Next Generation microbiome testing product range launched in Australia
Next Generation microbiome testing product range launched in Australia to healthcare professionals For personal use only Large addressable market >30% of the population suffer from a disorder of gut‐brain interaction (DGBI) related to the bowel1 >20% of the population is estimated to suffer from a c
Slide 10: MetaXplore the most comprehensive GI testing solution available on market
MetaXplore™ the most comprehensive GI testing solution available on market For personal use only 25+ Leading the clinical application of microbiome testing through Markers for gastrointestinal and microbiome health. comprehensive assessment of gastrointestinal and microbiome health 100+ to advance t
Slide 11: Partner distribution model
Partner distribution model Scalable global testing services For personal use only Testing Report Data Insights Customer Digital health sample collection Scalable cloud infrastructure report delivery 10
Slide 12: Microba's leading international bench of healthcare partners
Microba’s leading international bench of healthcare partners For personal use only $9.3bn Revenue $5.8bn Revenue Partnership: UK, Germany, Leading GI Diagnostics in US Raised USD $800m Partnership: Europe Belgium, Australia, US, Partnership: US Partnership: GCC Region & LATAM NZ & Switzerland Microb
Slide 13: Significant international distribution expansion for Microba's testing services
Significant international distribution expansion for Microba’s testing services For personal use only Access into 35 countries Operations activated in 8 of 35 countries Significant growth prospects ahead Coloured map depicts countries with binding distribution terms, and additional countries planned
Slide 14: Accelerating expansion and adoption
Accelerating expansion and adoption For personal use only # Distributors # Countries Operational Leading bench Launch & Early Major Market Further Country of healthcare COVID-19 Period partners provides Adopters Partnerships Expansion 12 access into 35 countries 10 Staged rollout being executed 8 to
Slide 15: Microbiome Therapeutics
For personal use only Microbiome Therapeutics Developing novel monoclonal microbial cell therapies 14
Slide 16: A therapeutic revolution. Novel, precision microbiome therapeutics
A therapeutic revolution. Novel, precision microbiome therapeutics For personal use only Precision Microbiome Therapeutics Innovative Pipeline Precision microbiome analysis platform delivering Excellent safety profile unparalleled accuracy, coverage & depth. Scalable GMP manufacturing for high
Slide 17: Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies
Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies For personal use only Monoclonal Population Identify AI & Advanced Disease microbial testing groups Biostatistics Models drug lead Healthy Orally administered, healthy Disease human donor derived, monocl
Slide 18: Rapid progress tapping the therapeutic potential of the human microbiome
Rapid progress tapping the therapeutic potential of the human microbiome for major chronic diseases For personal use only Inflammatory Bowel Disease Cancer Immunotherapy Autoimmune Diseases PROGRESSING TO PHASE I PRECLINICAL SCREENING Recently Completed Recently Completed Recently Completed Manufa
Slide 19: Inflammatory Bowel Disease program – MAP 315
Inflammatory Bowel Disease program – MAP 315 Addressing a key gap in existing therapy for UC sufferers For personal use only Ulcerative Colitis Addressable Ulcerative Colitis Therapeutic Patient Population1 Global Market Size2 MAP 315 has the potential to (% of total) Mild Moderate Severe ($USD Bill
Slide 20: Progressing into a first in human clinical trial
Inflammatory Bowel Disease program – MAP 315 Progressing into a first in human clinical trial For personal use only MANUFACTURING THROUGH TO FDA PRE-IND MEETING POSITIVE DRUG PRODUCT OUTCOME MAP 315 engineering production • Positive formal feedback from the through to full encapsulated drug FDA on P
Slide 21: Positive first animal data for Cancer Program
Positive first animal data for Cancer Program For personal use only Positive animal efficacy data has been generated for Microba’s immuno- oncology therapeutic leads. A significant reduction in tumour size was observed in combination with immune checkpoint inhibitor (ICI) treatment in a mouse model
Slide 22: The start of a therapeutic revolution
The start of a therapeutic revolution For personal use only APPROVED 30 Nov 2022 Faecal donor derived enema drug product RECENT FDA APPROVAL HAS CLEARED THE PATH TO MARKET 26 April PDUFA date for FOR LIVE MICROBIOME DRUGS, anticipated FDA approval Faecal donor derived oral A NEW MODALITY. capsule dr
Slide 23: Outlook
For personal use only Outlook 22
Slide 24: Upcoming Milestones for FY23
Upcoming Milestones for FY23 2023 2023 For personal use only JAN - MAR APR - JUN Services New healthcare product full launch Services New international distribution deals Therapeutics - IBD MAP315 program Phase 1 HREC Submission Therapeutics - IBD MAP315 program FDA Pre-IND meeting outcome Services
Slide 25: Contact
Contact For personal use only Dr Luke Reid Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Princess Alexandra Hospital Chairman Woolloongabba QLD Australia pasquale.rombola@microba.com
Microba Life Sciences — NWR Virtual Healthcare Investor Conference 2023 on 6ix